ArticleHepatology communications2025
Hepatocyte-derived Pumilio1-enriched exosomes inhibit HSC activation by suppressing tropomyosin-4 translation.
Article in Hepatology communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Extracellular Vesicle-Mediated Local and Systemic Communication in Metabolic Diseases.International journal of molecular sciences · 2026Review
- Extracellular Vesicles: Orchestrators of Intrahepatic and Systemic Crosstalk in Metabolic Dysfunction-Associated Steatotic Liver Disease.Pharmaceutics · 2026Review
- Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation.Biology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMetabolic dysfunction-associated steatotic liver disease (MASLD) has become the most common chronic liver disease globally. Abnormal crosstalk between hepatocytes and HSCs leads to liver fibrosis and aggravates MASLD. We explored the role of the RNA-binding protein Pumilio in this process.
methodsTwo isoforms of Pumilio proteins (PUM1, PUM2) expression were analyzed in the livers of MASLD patients and mice. MASLD mice were induced by a western diet combined with intraperitoneal injection of carbon tetrachloride (WD+CCl4), or a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD). Adeno-associated virus type 8 carrying Pum1-targeting short hairpin RNA or small interfering RNA targeting PUM1 was used to knock down PUM1 in vivo or in vitro. Ultracentrifugation was used to isolate exosomes from cells and serum. RNA sequencing and RNA immunoprecipitation experiments were used to find and identify the target genes of PUM1.
resultsThe expression of PUM1, not PUM2, was decreased in both MASLD patients and models. PUM1 knockdown aggravated liver injury. PUM1 also decreased in steatotic hepatocytes. Upregulating PUM1 improved lipid deposition and reduced hepatocyte lipotoxic death. Hepatocytes regulate the activation of HSCs by PUM1-enriched exosomes. Tropomyosin 4 (TPM4) was identified as a target of PUM1. PUM1 affected the expression of TPM4 by binding to its mRNA, thereby regulating HSCs activation.
conclusionsWhile PUM1 is downregulated during MASLD progression, upregulation of PUM1 improves lipid deposition, reduces hepatocyte lipotoxic death and inhibits TPM4 expression to reduce HSC activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.